small molecule

IQIRVO

ELAFIBRANOR

Loss of exclusivityMarch 2037latest FDA-listed patent expiry

CompanyIPSEN BIOPHARMACEUTICALS INC

Drug detail

Brand name	IQIRVO
Active ingredient	ELAFIBRANOR
Strength	80MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	June 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
11857523	March 2037	use U-3955
11850223	March 2037	use U-1854
11331292	March 2037	use U-1854
11185519	March 2037	use U-3955
12310935	March 2037	use U-1854
12295928	March 2037	use U-1854
12295927	March 2037	use U-1854
12233038	March 2037	use U-1854
12589086	March 2037	use U-4473

Regulatory exclusivity

Code	Expires
ODE-486	June 2031
NCE	June 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from IPSEN BIOPHARMACEUTICALS INC